Patients with resected stage III colon cancer who were 18 years of age or older , with an Eastern Cooperative Oncology Group performance status of 0 or 1 , from four randomised controlled trials ( NSABP C-08 , XELOXA , X-ACT , and AVANT ; 8734 patients in total ) were pooled and analysed .